|
Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines |
Combined Measles, Mumps, Rubella, Varicella Vaccine |
208136/038 |
|
Measles; Mumps; Rubella; Varicella |
Phase 3 |
|
|
|
|
Follow-on studies 208136/039, 208136/040, and 208136/041 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
February 2015 |